

Otsuka ends gene therapy collaboraton with Takara Bio

14 November 2022 | News

Otsuka and Takara Bio have been jointly developing NY-ESO-1[?]siTCR gene therapy for synovial sarcoma in Japan



Japanese firm Otsuka Pharmaceutical has decided jointly with Takara Bio Inc, to terminate agreements on co-development and exclusive marketing of NY-ESO-1[?]siTCR gene therapy product (development code: TBI-1301).

Otsuka and Takara Bio have been jointly developing NY-ESO-1[?]siTCR gene therapy for synovial sarcoma in Japan and preparing for the submission for manufacturing and marketing approval. However after comprehensive discussions between the two companies on policies and strategies related to this product, Otsuka and Takara Bio have agreed to terminate this agreement. This decision is not due to any efficacy or safety issues of the product.

Under this termination, Takara Bio regains technical, intellectual property and other rights granted by Takara Bio to Otsuka. In addition, in the future Takara Bio will not receive lump-sum payments upon achievement of milestones under this agreement or receive any sales proceeds for clinical trial product sales.